GLP-1 Medications and
Fatty Liver Disease

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the newer name for a common condition previously called nonalcoholic fatty liver disease. Its inflammatory, potentially progressive form is metabolic dysfunction-associated steatohepatitis (MASH), formerly NASH. The terminology matters because simple fat accumulation, active steatohepatitis, fibrosis, and cirrhosis carry different risks and treatment implications.

MASLD and MASH are a spectrum—not interchangeable labels

MASLD describes excess liver fat in the context of metabolic risk. MASH adds liver-cell injury and inflammation. Fibrosis describes scar tissue, commonly staged from F0 through F4; F4 generally represents cirrhosis. A person may have no obvious symptoms even when clinically important disease is present, so fatigue or abdominal discomfort cannot confirm or exclude it.^{[1] [4]}

Evaluation may include medical history, alcohol and medication review, liver enzymes, metabolic testing, noninvasive fibrosis scores, imaging or elastography, and sometimes liver biopsy. A routine scan that says “fatty liver” does not by itself establish MASH or the fibrosis stage used in medication trials and FDA labeling.

This distinction also affects how trial results should be interpreted. The major semaglutide and tirzepatide MASH trials required biopsy-confirmed disease and moderate-to-advanced fibrosis; they did not simply enroll anyone with obesity, elevated liver enzymes, or liver fat on an ultrasound. Patients should not assume they match the studied population without an appropriate diagnostic assessment.^{[3] [5]}

What exactly did the FDA approve?

In August 2025, FDA approved Wegovy injection for adults with noncirrhotic MASH and moderate-to-advanced fibrosis consistent with stages F2 to F3. The indication is used with a reduced-calorie diet and increased physical activity. Approval was granted through the accelerated approval pathway, meaning it was based on improvement in liver histology while a longer trial continues to assess clinical outcomes such as liver-related events.^{[1] [2]}

What the ESSENCE semaglutide trial found

ESSENCE is an ongoing phase 3 randomized, double-blind, placebo-controlled trial enrolling 1,197 people with biopsy-defined MASH and F2 or F3 fibrosis. The planned 72-week interim analysis included the first 800 participants: 534 received semaglutide 2.4 mg weekly and 266 received placebo, alongside lifestyle intervention.^{[1] [5]}

These results are clinically meaningful, but they are interim histology findings. The trial is continuing to 240 weeks to evaluate whether improvements translate into fewer liver-related complications, transplants, or deaths. Gastrointestinal adverse events were more common with semaglutide.^[5]

What about tirzepatide?

The phase 2 SYNERGY-NASH trial studied 190 people with biopsy-confirmed MASH and F2–F3 fibrosis. Participants received tirzepatide 5 mg, 10 mg, 15 mg, or placebo weekly for 52 weeks. MASH resolution without worsening fibrosis occurred in 44%, 56%, and 62% of the three tirzepatide groups, respectively, versus 10% with placebo. Improvement of at least one fibrosis stage without worsening MASH occurred in 55%, 51%, and 51% versus 30%.^[3]

The study was dose-finding, lasted one year, and had 157 evaluable week-52 biopsies. Its authors called for larger and longer trials. Current Zepbound labeling includes chronic weight management and obesity-related obstructive sleep apnea indications, not a MASH indication. Promising trial results should not be described as an approval or as proof of long-term liver-outcome benefit.^{[3] [6]}

How much of the benefit comes from weight loss?

Weight reduction can decrease liver fat and may improve inflammation and fibrosis. NIDDK states that losing at least 3%–5% of body weight can reduce liver fat and that 7%–10% may be needed to reduce inflammation and fibrosis; physical activity can help even without weight loss. Weight should be lost gradually because rapid loss and malnutrition can worsen liver disease.^[4]

GLP-1 therapies also affect glucose regulation, appetite, insulin sensitivity, and other metabolic pathways. Current trials cannot reduce the liver response to a single mechanism. The practical takeaway is not that weight loss alone substitutes for liver evaluation, but that liver care and obesity care often need to be coordinated.

What comprehensive care still includes

• Confirming disease stage. Treatment decisions differ for steatosis, MASH, F2–F3 fibrosis, and cirrhosis.
• Managing metabolic risk. Diabetes, blood pressure, lipids, sleep apnea, and cardiovascular risk can affect both liver and overall outcomes.
• Nutrition and physical activity. These remain part of care even when medication is used.^[4]
• Medication safety. Clinicians should review contraindications, gastrointestinal symptoms, gallbladder and pancreas concerns, kidney risk from dehydration, pregnancy plans, and all other medicines.^{[2] [6]}
• Specialist coordination. People with advanced fibrosis, uncertain staging, cirrhosis, or abnormal tests may need hepatology or gastroenterology involvement.

What the evidence does not establish

The evidence does not show that any online symptom list can diagnose MASH, that normal liver enzymes rule it out, or that every GLP-1 product has a liver-disease indication. It also does not establish that a compounded product is FDA-approved for MASH. Compounded semaglutide and tirzepatide are not FDA-approved products and should not be represented as equivalent to an FDA-approved product for a specific liver indication.

AASLD’s updated guidance focuses on clinician selection of patients with MASH and F2–F3 fibrosis, management of comorbidities, and monitoring semaglutide safety and effectiveness. That reinforces a specialist-guided approach rather than self-treatment based on a scan result alone.^[7]

Frequently asked questions